Sight Sciences is exhibiting a promising revenue inflection, with growth accelerating to 19.5% year-over-year in 2026Q2 on the back of best-in-class 91.4% gross margins.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.12+2.6% vs -$0.12 | $25M+5.8% vs $24M |
Q3 2026 Aug 5, 2026 | -$0.08+56.4% vs -$0.18 | $23M+7.7% vs $22M |
Q2 2026 May 6, 2026 | -$0.24-26.3% vs -$0.19 | $20M+6.7% vs $18M |
Q2 2026 Mar 4, 2026 | -$0.08+46.7% vs -$0.15 | $20M+0.2% vs $20M |
Shares of Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new direct practice expense supply code for the single-use TearCare SmartLids® component of the TearCare® System (TearCare).
Sight Sciences NASDAQ: SGHT raised its full-year revenue outlook after reporting record third-quarter sales, driven by growth in its glaucoma business and increased adoption of its TearCare dry eye treatment.
Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript
Benchmark SGHT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sight Sciences, Inc. (SGHT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.08 | $548.45M | -19.57 | -3.13% | -32.13% | -51.66% | — | |
| $224.41 | $13.24B | -80.88 | 32.33% | -24.6% | -24.91% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% |
Sight Sciences, Inc. (SGHT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sight Sciences, Inc. (SGHT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 5, 2026·SEC
Jun 5, 2026·SEC
Get notified when SGHT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sight Sciences, Inc. (SGHT) stock FAQ — growth, dividends, profitability & financials explained
Sight Sciences, Inc. (SGHT) reported $88.4M in revenue over the trailing twelve months. Revenue was $77.4M in fiscal year 2025. That is 927% more than the $7.5M of fiscal year 2018.
Sight Sciences, Inc. (SGHT) grew revenue by 16.2% over the trailing twelve months, compared with the twelve months before.
No. Sight Sciences, Inc. (SGHT) reported a net loss of $28.4M over the trailing twelve months.
Sight Sciences, Inc. (SGHT) had a return on equity (ROE) of -51.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Sight Sciences, Inc. (SGHT) had negative free cash flow of $16.9M over the trailing twelve months.
